Cambridge Investment Research Advisors’s Progyny PGNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$690K Buy
23,932
+413
+2% +$9.23K ﹤0.01% 2652
2026
Q1
$399K Sell
23,519
-1,231
-5% -$26.4K ﹤0.01% 3009
2025
Q4
$636K Sell
24,750
-9,714
-28% -$223K ﹤0.01% 2501
2025
Q3
$742K Buy
34,464
+13,993
+68% +$318K ﹤0.01% 2298
2025
Q2
$450K Sell
20,471
-177
-0.9% -$3.88K ﹤0.01% 2641
2025
Q1
$461K Sell
20,648
-100
-0.5% -$2.15K ﹤0.01% 2524
2024
Q4
$358K Buy
20,748
+7,392
+55% +$115K ﹤0.01% 2696
2024
Q3
$224K Buy
+13,356
New +$321K ﹤0.01% 3054
2022
Q2
Sell
-3,897
Closed -$200K 3174
2022
Q1
$200K Sell
3,897
-3,017
-44% -$129K ﹤0.01% 2876
2021
Q4
$348K Sell
6,914
-126
-2% -$7.05K ﹤0.01% 2397
2021
Q3
$394K Buy
7,040
+456
+7% +$25.2K ﹤0.01% 2231
2021
Q2
$388K Buy
+6,584
New +$370K ﹤0.01% 2264

Other funds holding PGNY

Cambridge Investment Research Advisors's PGNY Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Progyny (PGNY) stake by 1.8% in Q2 2026, buying an estimated $9.23K and bringing the position to 23,932 shares worth $690K. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Cambridge Investment Research Advisors first reported a position in PGNY in Q2 2021 and has held it in 12 quarters since. The position peaked at $742K in Q3 2025. 70 funds tracked by Wall St. Rank hold PGNY as of Q2 2026.

  • Cambridge Investment Research Advisors held 23,932 shares of Progyny worth $690K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 413 Progyny shares in Q2 2026, an estimated $9.23K.
  • Progyny made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2652 holding.
  • Cambridge Investment Research Advisors first reported a position in Progyny in Q2 2021 and has held it in 12 quarters since.
  • Cambridge Investment Research Advisors's Progyny position peaked at $742K in Q3 2025.
  • 70 funds tracked by Wall St. Rank held Progyny as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.